Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, autism or bipolar disorder, who develop new impulse control disorders or worsening pre-existing impulse control traits after dopamine agonist exposure; and whether similar data are available for Parkinson’s disease patients with those co-morbidities.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b) the combinations of (i) hypersexuality, (ii) binge eating, (iii) compulsive shopping, (iv) compulsive gambling and (v) risky investments that are most commonly reported.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including attention deficit hyperactivity disorder, autism or bipolar disorder; and how many had documented impulse control disorders or addictive behaviours before dopamine agonist initiation.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy, pre-existing depression or anxiety, attention deficit hyperactivity disorder, autism, bipolar disorder and prior addictive or impulsive behaviours.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c) bringing a legal claim relating to dopamine agonist-associated impulse control disorders.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who require dose escalation and (c) the typical timing and magnitude of such escalation.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (b) formal recognition and recording of dopamine agonist-associated impulse control disorders; and how those intervals vary by indication, care setting and method of detection.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential dopamine agonist-related impulse control disorders and augmentation from prescribing and clinical records and (b) support earlier warnings and monitoring for patients at higher risk.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, including anxiety, depression, autonomic symptoms, pain and craving.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse control disorders are first reported by a family member, carer or other third party.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonist treatment and (b) are able to stop or switch treatment.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among women treated with dopamine agonists who have documented impulse control disorder-related hypersexual behaviours; and whether patients are routinely asked about current dopamine agonist use in abortion and sexual health services.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine agonist-related impulse control disorders and augmentation, (b) monitoring for behavioural side effects at follow-up and (c) documenting impulse control disorders in a retrievable format for audit and research.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical education; and what postgraduate or continuing professional development training is available on dopamine agonist-related impulse control disorders, augmentation and withdrawal syndromes.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while taking dopamine agonists, including the option of recording the patient’s wishes about dose reduction or discontinuation.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the incidence of new-onset diabetes or serious obesity-related complications in that group and (d) how those findings affect prescribing or dose decisions.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the level of suicides and attempted suicides among (a) people prescribed dopamine agonists who have experienced impulse control disorders, augmentation or dopamine agonist withdrawal syndrome and (b) immediate family members or co-habitants affected by the consequences of a relative’s dopamine agonist-induced impulse control disorder.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of dopamine agonist-related impulse control disorders and augmentation in people with restless legs syndrome and Parkinson’s disease on the economy, including effects on (a) employment and loss of earnings, (b) welfare and benefits claims and (c) mental health service use by patients and affected family members.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential financial impact of dopamine agonist-related impulse control disorders on those experiencing such disorders, including through (a) gambling-related behaviours, (b) compulsive buying and (c) other routes.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on the number and proportion of dopamine agonist-treated patients with impulse control disorders who experience relationship breakdown or divorce.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients can access the most effective innovations for migraine.

Answered by Preet Kaur Gill

The National Institute for Health and Care Excellence (NICE) has recommended several new medicines as options for the treatment of migraine. The National Health Service in England is legally required to fund medicines recommended in a NICE appraisal, usually within three months of final guidance.

The NHS England Neurology Transformation Programme has developed a neurology toolkit for integrated care boards (ICBs) which includes guidance on optimising system-wide headache pathways, including for migraine. This guidance will provide support to ICBs in reducing regional variation in access to NICE-recommended Calcitonin Gene-Related Peptide and gepant migraine treatments for patients, including options for improving community-based services that reduce outpatient waiting lists and improve timely access to diagnosis and treatment.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number and proportion of patients who, having developed impulse control disorders while taking dopamine agonists and attempted withdrawal, subsequently return to their previous dopamine agonist dose or restart a dopamine agonist where withdrawal symptoms were recorded as the reason.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdrawal syndrome, when dopamine agonists are reduced or stopped in routine clinical practice in the last five years.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the typical duration and severity of withdrawal symptoms associated with dopamine agonist dose reduction or discontinuation; and how those outcomes vary by starting dose, indication and duration of exposure.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the extent of under-reporting of dopamine agonist-related impulse control disorders to the Yellow Card scheme; and what steps it is taking to improve reporting and capture of those events.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients exposed to dopamine agonists for (a) Parkinson’s disease and (b) restless legs syndrome; and what comparison the Department has made between (i) the number of Yellow Card reports of impulse control disorders associated with those medicines and (ii) prevalence rates of those disorders reported in large clinical cohorts in the UK over the last 20 years.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many Yellow Card reports have (a) listed pramipexole, ropinirole, rotigotine and cabergoline as a suspected medicine and (b) included any reaction term relating to impulse control disorders, including pathological gambling, hypersexuality, compulsive buying, binge eating or other compulsive behaviours during the last 20 years.

Answered by Preet Kaur Gill

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Secretary of State for Health and Social Care on cross-government support for people whose ability to work is affected by migraine.

Answered by Sharon Hodgson

The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and Health Directorate was established to co-ordinate Government activity to help disabled people and people with health conditions get good work, get on in that work, and to return to work as quickly as possible if they leave it.

The Department of Health and Social Care and the Department for Work and Pensions have a range of specialist initiatives, including those joining up health and employment support around the individual through programmes such as Employment Advisors in NHS Talking Therapies and WorkWell, as well as support from Work Coaches and Disability Employment Advisers in Jobcentres and Access to Work grants. Ministers and officials have regular conversations with regard to employment support for people whose ability to work is affected by a health condition.

The Government’s 10-Year Health Plan, published in July 2025, builds on existing work to better integrate health with employment support and incentivise greater cross-system collaboration. The plan outlines how the neighbourhood health service will join up support from across the work, health, and skills systems to help address the multiple complex challenges that often stop people finding and staying in work and deliver holistic care that leads to better employment outcomes for all.

Employers are also crucial in enhancing employment opportunities and supporting disabled people and people with health conditions, such as migraines, to thrive in the workforce. To encourage employers to create disability inclusive workplaces, the Government continues to oversee the Disability Confident Scheme. This provides resources such as the Disability Confident Manager’s Guide, which includes guidance on flexible working and workplace adjustments, and which is available at the following link:

https://www.gov.uk/government/publications/disability-confident-and-cipd-guide-for-line-managers-on-employing-people-with-a-disability-or-health-condition

The Government’s offer to employers also comprises tailored guidance on supporting disabled people and people with health conditions in the workplace through its Support with Employee Health and Disability service. This includes guidance on disclosures and having conversations about health and disabilities, plus guidance on legal obligations and making reasonable adjustments. Further information on the Support with Employee Health and Disability service is available at the following link:

https://www.support-with-employee-health-and-disability.dwp.gov.uk/support-with-employee-health-and-disability

Additionally, in November 2025, Sir Charlie Mayfield published the Keep Britain Working Review, setting out recommendations to reshape how the Government works with employers to improve work and health outcomes through creating healthier, more inclusive workplaces. The Government is now working with volunteer employers, providers, and regions through a Vanguard Phase to test and refine approaches to help disabled workers and workers with long-term health conditions, including people affected by migraine, receive the support they need to remain and thrive in employment. Alongside the Department of Health and Social Care, the Department for Work and Pensions, and the Department for Business and Trade, National Health Service organisations are already participating in the Keep Britain Working Vanguard Phase to design a healthy working lifecycle standard and the accompanying Workplace Health Provision.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage employers to provide reasonable workplace support for employees affected by migraine.

Answered by Sharon Hodgson

The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and Health Directorate was established to co-ordinate Government activity to help disabled people and people with health conditions get good work, get on in that work, and to return to work as quickly as possible if they leave it.

The Department of Health and Social Care and the Department for Work and Pensions have a range of specialist initiatives, including those joining up health and employment support around the individual through programmes such as Employment Advisors in NHS Talking Therapies and WorkWell, as well as support from Work Coaches and Disability Employment Advisers in Jobcentres and Access to Work grants. Ministers and officials have regular conversations with regard to employment support for people whose ability to work is affected by a health condition.

The Government’s 10-Year Health Plan, published in July 2025, builds on existing work to better integrate health with employment support and incentivise greater cross-system collaboration. The plan outlines how the neighbourhood health service will join up support from across the work, health, and skills systems to help address the multiple complex challenges that often stop people finding and staying in work and deliver holistic care that leads to better employment outcomes for all.

Employers are also crucial in enhancing employment opportunities and supporting disabled people and people with health conditions, such as migraines, to thrive in the workforce. To encourage employers to create disability inclusive workplaces, the Government continues to oversee the Disability Confident Scheme. This provides resources such as the Disability Confident Manager’s Guide, which includes guidance on flexible working and workplace adjustments, and which is available at the following link:

https://www.gov.uk/government/publications/disability-confident-and-cipd-guide-for-line-managers-on-employing-people-with-a-disability-or-health-condition

The Government’s offer to employers also comprises tailored guidance on supporting disabled people and people with health conditions in the workplace through its Support with Employee Health and Disability service. This includes guidance on disclosures and having conversations about health and disabilities, plus guidance on legal obligations and making reasonable adjustments. Further information on the Support with Employee Health and Disability service is available at the following link:

https://www.support-with-employee-health-and-disability.dwp.gov.uk/support-with-employee-health-and-disability

Additionally, in November 2025, Sir Charlie Mayfield published the Keep Britain Working Review, setting out recommendations to reshape how the Government works with employers to improve work and health outcomes through creating healthier, more inclusive workplaces. The Government is now working with volunteer employers, providers, and regions through a Vanguard Phase to test and refine approaches to help disabled workers and workers with long-term health conditions, including people affected by migraine, receive the support they need to remain and thrive in employment. Alongside the Department of Health and Social Care, the Department for Work and Pensions, and the Department for Business and Trade, National Health Service organisations are already participating in the Keep Britain Working Vanguard Phase to design a healthy working lifecycle standard and the accompanying Workplace Health Provision.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve outcomes for people living with migraine.

Answered by Sharon Hodgson

The Government recognises the significant impact that migraine can have on individuals’ quality of life and is committed to improving care and outcomes for people living with this condition.

NHS England is supporting improvements in migraine care through national programmes such as the RightCare headache and migraine toolkit and the Getting It Right First Time neurology programme. These initiatives support earlier diagnosis, more effective management in primary care, and better access to specialist services where needed, helping to reduce unwarranted variation in care and improve patient outcomes.

To support consistent, high-quality care, the National Institute for Health and Care Excellence (NICE) has published clear, evidence-based guidance on the diagnosis and management of headaches, including migraine. This guidance helps clinicians to diagnose migraine more promptly and provide appropriate acute and preventive treatments based on individual clinical need.

In August 2025, NHS England updated its service specification for specialised adult neurology services. It outlines a number of minimum service requirements for key specialties, including complex headache services.

Over the last five years, a new class of drugs, calcitonin gene-related peptide (CGRP) inhibitors, has been made available on the National Health Service for the prevention and treatment of episodic and chronic migraines. Atogepant is the latest CGRP inhibitor to be recommended by NICE for use as a prevention and acute treatment of migraine.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will ensure that the Government provides, by 16 July 2026, the information requested by the Patient Safety Commissioner on (a) action taken in response to the Hughes Report, (b) outstanding steps required before Ministers can decide on redress and (c) a timetable for the Government’s full response, including on the establishment of compensation schemes for those harmed by pelvic mesh and sodium valproate.

Answered by Preet Kaur Gill

The Patient Safety Commissioner wrote to the Prime Minister on 16 June, requesting information regarding internal and cross-Government discussions in relation to the Hughes Report, actions that have been taken beyond the Department, and the future plans regarding the implementation of its recommendations and a timetable for a full response.

The Department will provide any information required to support a timely response.

Question to the Department for Transport:

To ask the Secretary of State for Transport, pursuant to the Answer of 17 April 2026 to Question 123626 on Aviation: Crew, if she will provide the number of commercial airline pilots registered with the Civil Aviation Authority who (a) reached the mandatory retirement age of 65 in each of the past five calendar years and (b) will reach the mandatory retirement age of 65 in each of the next 10 calendar years.

Answered by Keir Mather - Parliamentary Under-Secretary (Department for Transport)

The data below accounts for all relevant commercial licence types and relates to pilots who reached the age of 65 during the relevant report year and held a valid commercial licence and valid medical certificate as of 1 January of that year.

The number of pilots that will reach the mandatory age of 65 in the next 10 calendar years can be found on the Civil Aviation Authority’s published data on pilot licence holders by age and sex, which can be found here: https://www.caa.co.uk/data-and-analysis/approved-persons-and-organisations/personnel-licensing-statistics/pilot-licence-holders-by-age-and-sex/ . The data for 2025 will be published in the next few months.

Question to the Department for Transport:

To ask the Secretary of State for Transport, how many commercial airline pilots joined the Civil Aviation Authority register in each of the past five calendar years.

Answered by Keir Mather - Parliamentary Under-Secretary (Department for Transport)

The table below shows the number of pilots that received their first UK commercial pilot licence from the Civil Aviation Authority by year of issue and includes all relevant commercial licence types.

Carbon monoxide alarms

Key Stage 2 Sats Results and the Pearson-Administered National Curriculum Assessment

Found: Charalambous; Sir Christopher Chope; Mary Kelly Foy; John Lamont; Tom Morrison; Katrina Murray; Lee Pitcher